Literature DB >> 10882607

Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.

A H Groll1, N Giri, V Petraitis, R Petraitiene, M Candelario, J S Bacher, S C Piscitelli, T J Walsh.   

Abstract

The central nervous system (CNS) distribution and antifungal efficacy of all 4 approved formulations of amphotericin B (AmB) were investigated in a rabbit model of hematogenous Candida albicans meningoencephalitis. Treatment with AmB deoxycholate (1 mg/kg/day) or liposomal AmB (5 mg/kg/day) yielded the highest peak plasma concentration (C(max)), area under concentration versus time curve from zero to 24 h (AUC(0-24)), and time during dosing level tau Ttau>minimum inhibitory complex (MIC) values and led to complete eradication of C. albicans from brain tissue (P<.05 vs. untreated controls). By comparison, AmB colloidal dispersion and AmB lipid complex (5 mg/kg/day each) were only partially effective (not significant vs. untreated controls). There was a strong correlation of C(max), AUC(0-24), C(max)/MIC, AUC(0-24)/MIC, and Ttau>MIC with clearance of C. albicans from brain tissue (P</=.0002). Although pharmacodynamic parameters derived from the MIC of free AmB were highly predictive of antifungal efficacy, parameters derived from MICs of individual formulations were not predictive. AmB deoxycholate and liposomal AmB had the greatest antifungal efficacy. This activity was concentration and time dependent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882607     DOI: 10.1086/315643

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  100 in total

1.  Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis.

Authors:  Amy M Flattery; Emily Hickey; Charles J Gill; Mary Ann Powles; Andrew S Misura; Andrew M Galgoci; Joan D Ellis; Rena Zhang; Punam Sandhu; John Ronan; George K Abruzzo
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits.

Authors:  Andreas H Groll; Diana Mickiene; Vidmantas Petraitis; Ruta Petraitiene; Raul M Alfaro; Christine King; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 3.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

4.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 5.  Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Authors:  B Milojkovic Kerklaan; O van Tellingen; A D R Huitema; J H Beijnen; W Boogerd; J H M Schellens; D Brandsma
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

6.  Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Bo Bo Win Maung; Robert S Mansbach; Michael R Hodges; Malcolm A Finkelman; Karen Joy Shaw; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

7.  Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.

Authors:  Jon A Olson; Jill P Adler-Moore; Julie Schwartz; Gerard M Jensen; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

8.  Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

9.  Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans.

Authors:  Scott W Mueller; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2011-03-26

10.  Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits.

Authors:  Karl V Clemons; Raymond A Sobel; Paul L Williams; Demosthenes Pappagianis; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.